FILING ANALYSIS · THURSDAY, OCTOBER 29
BRISTOL MYERS SQUIBB CO BMY — 8-K: Results of Operations and Financial Condition
positive
Bristol Myers Squibb reported a 7% increase in third-quarter revenues to $13.1 billion and raised its full-year revenue guidance, driven by strong performance in its Growth Portfolio, which includes Opdivo, Opdivo Qvantig, and Breyanzi. The company's non-GAAP EPS was $1.35, including a net impact of $(0.58) due to Acquired IPRD charges and licensing income.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →